With Oral Anti-Obesity Candidate Development, Pfizer Seeks Relevant And Competitive Presence - Goldman Sachs
Pfizer has selected its preferred once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, with dose optimization studies planned for late 2024. The study will evaluate multiple doses to inform registration enabling studies, aiming to address previous Phase 2b BID study's GI-related adverse events.